BullFrog AI Announces Appointment of Enrique García-Rivera as Vice President of Artificial Intelligence

New VP will enhance development of industry-leading bfLEAP™ AI platform to accelerate and optimize drug discovery process

GAITHERSBURG, Md., July 11, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a precision medicine company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Enrique García-Rivera, Ph.D., as its new Vice President of Artificial Intelligence. The appointment will further advance BullFrog AI’s best-in-class proprietary bfLEAP™ AI platform that is engineered to enable more accurate predictions of patient disease progression and improve the design of clinical trials to speed safe and effective drug development.

“We are excited to welcome Enrique to BullFrog AI. His exceptional track record in AI and biomedical research, coupled with his unique ability to translate complex data into meaningful insights, will further bolster the capability of our bfLEAP™ AI platform to glean insights from incomplete data sets, perform multimodal analysis and reveal valuable patterns and relationships across deep and wide nodes of unstructured data,” commented Vin Singh, CEO of BullFrog AI. “I am confident that his expertise will drive our bfLEAP™ AI platform to new heights and strengthen our position at the forefront of AI-driven drug development, ultimately paving the way for more effective and personalized therapeutic solutions.”

Prior to joining BullFrog AI, Dr. García-Rivera held leadership roles at ROME Therapeutics and nference in Cambridge, MA. At ROME Therapeutics, he led clinical applications and platform engineering, and while at nference, he developed a drug discovery platform and led various research efforts. Previously Dr. García-Rivera was a research associate at the Broad Institute of Harvard and MIT, where he identified a novel kinase dependency in synovial sarcomas through large-scale small molecule profiling. His vast experience in developing machine learning models and managing large biological databases further augments BullFrog AI’s industry-leading capabilities.

“In a few short years, BullFrog AI has demonstrated the potential of its bfLEAP™ AI platform to identify new drug targets and predict patient outcomes, accelerating drug development and enabling optimized clinical trial design,” stated Dr. García-Rivera. “I look forward to joining such a talented team dedicated to pushing the boundaries and fulfilling the promise of artificial intelligence in pharmaceutical research and development.”

Dr. García-Rivera holds a Ph.D. in Biological and Biomedical Sciences (Chemical Biology) from Harvard University and a BS in Interdisciplinary Sciences from the University of Puerto Rico.

About BullFrog AI

BullFrog AI is a precision medicine company using AI and machine learning to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. Through its collaborations with leading research institutions, including Johns Hopkins University, BullFrog AI is at the forefront of AI-driven drug development using its proprietary bfLEAP™ artificial intelligence platform. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics.

For more information visit BullFrog AI at:

Website: https://bullfrogai.com

LinkedIn: https://www.linkedin.com/company/bullfrogai/

Safe Harbor Statement

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Contact:

Investors
Dave Gentry
RedChip Companies, Inc.
BFRG@redchip.com
800-733-2447

Media
Tiberend Strategic Advisors, Inc.
Eric Reiss
Ereiss@tiberend.com
802-249-1136

Dave Schemelia
Dschemelia@tiberend.com
609-468-9325

SOURCE: BullFrog AI Holdings, Inc.

Released July 11, 2023